RB
Insider buying
Ron Bentsur bought $250K of NVCT stock
Ron Bentsur, Chairman & CEO, 10% of Nuvectis Pharma, Inc. (NVCT), bought 12,500 shares of NVCT stock worth $250K, per an SEC Form 4 filed Jul 1, 2026.
The shares came through a private deal, not the open market.
The trade happened on Jun 30, 2026, 1 day before it was made public.
NVCT has moved +12.6% since the trade date, from $18.39 to $20.70 (Oct 21, 2026 close).
- Traded
- Jun 30, 2026
- Disclosed
- Jul 1, 2026
- Filing delay
- 1 day
- Price since
- +12.6%
- Role
- Chairman & CEO, 10%
- Source
- SEC Form 4
More NVCT insider and Congress trades
From a public SEC Form 4, linked above. Not investment advice, and not a recommendation to buy or sell.